Tumor Metabolome Targeting and Drug Development

Steven Kanner (Herausgeber)

Buch | Hardcover
198 Seiten
2014
Springer-Verlag New York Inc.
978-1-4614-9544-4 (ISBN)

Lese- und Medienproben

Tumor Metabolome Targeting and Drug Development -
160,49 inkl. MwSt
In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussions of former and emerging approaches to drug development in targeting cancer cell metabolism.

The metabolic network in cells promotes the generation of both energy and biomass needed for them to grow, divide and differentiate. However, the metabolism of malignant cells generally varies from that of normal cells. These differences provide a platform for the discovery of new approaches to targeting potential vulnerabilities in cancer cells for therapeutic options Some of the significant changes that occur involve ATP production and consumption that modulates the ATP to ADP ratio, hypoxia and the effects of reactive oxygen species on glycolysis, regulation of mitochondrial respiration, induction and suppression of autophagy, and the Warburg effect and “reverse” Warburg effect--these topics and more are discussed in this volume.

Dr. Steven B. Kanner is the Vice President of Discovery Biology at Astex Pharmaceuticals. He has been a pharmaceutical research leader with over 20 years of extensive experience in novel target identification and validation, assay development, both small molecule and antibody drug discovery, and expertise in oncology, immunology and inflammation. For more detail, please see the attached CV herewith.

Tumor cell metabolic reprogramming and drug targeting.- Cancer metabolism: a nexus of matter, energy and reactive oxygen species.- Regulating mitochondrial respiration in cancer.- Regulation of cancer cell metabolism by hypoxia.- Glucose metabolism and the anti-oxidative defence system in cancer cells: Options for application of ROS-based anticancer drugs.- Modulating autophagy and the “reverse Warburg effect”.- Metabolic adaptation in reprogrammed cancer cells.- Index.

Reihe/Serie Cancer Drug Discovery and Development
Zusatzinfo 12 Illustrations, color; 10 Illustrations, black and white; VIII, 198 p. 22 illus., 12 illus. in color.
Verlagsort New York, NY
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Studium
Naturwissenschaften Biologie Zellbiologie
Schlagworte drug development • Targeting • Tumor • tumor metabalome
ISBN-10 1-4614-9544-X / 146149544X
ISBN-13 978-1-4614-9544-4 / 9781461495444
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00

von Stein Husebø; Gebhard Mathis; Eva Katharina Masel

Buch | Softcover (2023)
Springer (Verlag)
49,99